Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  Astellas Pharma Inc    4503   JP3942400007

ASTELLAS PHARMA INC (4503)
Mes dernières consult.
Most popular
Report
 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ( JPY)
Sales 2018 1 289 B
EBIT 2018 220 B
Net income 2018 178 B
Finance 2018 368 B
Yield 2018 2,60%
Sales 2019 1 288 B
EBIT 2019 249 B
Net income 2019 194 B
Finance 2019 452 B
Yield 2019 2,73%
P/E ratio 2018 15,33
P/E ratio 2019 14,34
EV / Sales2018 1,93x
EV / Sales2019 1,87x
Capitalization 2 862 B
More Financials
Company
Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products.Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic... 
Sector
Pharmaceuticals
Calendar
01/31Earnings Release
More about the company
Surperformance© ratings of Astellas Pharma Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on ASTELLAS PHARMA INC
01/19 ASTELLAS PHARMA : Research Data from Astellas Pharma Update Understanding of Med..
01/19 ASTELLAS PHARMA : Reports Summarize Central Nervous System Agents Findings from ..
01/19 ASTELLAS PHARMA : New Pelvic Pain Study Findings Have Been Reported by Investiga..
01/15 AMGEN : Astellas Pharma Inc - Repatha SC Injection 420 mg Auto Mini Doser Launch..
01/12 ASTELLAS PHARMA : Submits Supplemental New Drug Application for Approval of Addi..
01/12 ASTELLAS PHARMA : Repatha® SC Injection 420 mg Auto Mini Doser Launched in Japan..
01/11 ASTELLAS PHARMA : Researchers from Astellas Pharma Report New Studies and Findin..
01/11 AMGEN : Astellas BioPharma K.K. - Application for Marketing Approval Submitted f..
01/11 ASTELLAS PHARMA : Submits Supplemental New Drug Application for Approval of Addi..
01/09 ASTELLAS PHARMA : Application for Marketing Approval Submitted for Bispecific CD..
More news
Sector news : Pharmaceuticals - NEC
01/19 CANADIAN CANNABIS FIRM AURORA IN TAL : sources
01/19 En route to Davos, Macron makes Versailles the place to be
01/19 SHIRE PLC SHIRE PLC : Directorate Change
01/19 At AstraZeneca, fewer drug projects bring big productivity jump
01/18 European shares edge higher as cyclicals back in favour
More sector news : Pharmaceuticals - NEC
Latest Tweets
01/12Astellas Pharma : Repatha® SC Injection 420 mg Auto Mini Doser Launched in Ja.. 
01/11Astellas Pharma : Submits Supplemental New Drug Application for Approval of A.. 
01/09Astellas Pharma’s Bernie Zeiher closes out the FierceBiotech Executive Breakf..
5
01/09Astellas Pharma : Application for Marketing Approval Submitted for Bispecific.. 
2017#Tokyo #stocks: Astellas Pharma : #Acquisition Analysts say tenuous Dec 2017.. 
More tweets
Qtime:41
News from SeekingAlpha
01/10 Astellas Pharma (ALPMY) Presents At 36th Annual J.P. Morgan Healthcare Confer..
2017 'Safer' Dividend Healthcare Gainers Glaxo, Pfizer & Medical Facilities Are Ta..
2017 Astellas Pharma acquiring Mitobridge for $225M
2017 3 THINGS IN BIOTECH YOU SHOULD LEARN : November 21, 2017
2017 YOUR DAILY PHARMA SCOOP : Valeant Remains Risky, Novartis's Kisqali, Tesaro Tumb..
Chart ASTELLAS PHARMA INC
Duration : Period :
Astellas Pharma Inc Technical Analysis Chart | 4503 | JP3942400007 | 4-Traders
Technical analysis trends ASTELLAS PHARMA INC
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 1 548  JPY
Spread / Average Target 12%
EPS Revisions
Managers
NameTitle
Yoshihiko Hatanaka President, CEO & Representative Director
Chikashi Takeda Chief Financial Officer
Mitsunori Matsuda Senior Executive Officer & President-Technology
Yoshiro Miyokawa Representative Director & Executive Vice President
Hironobu Yasuda Outside Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTELLAS PHARMA INC-4.55%25 854
JOHNSON & JOHNSON5.20%395 886
NOVARTIS0.61%227 592
PFIZER2.65%220 189
ROCHE HOLDING LTD.-5.40%211 135
MERCK AND COMPANY10.24%167 132